Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
- Biosensor platform leverages silicon semiconductor manufacturing for scale.
- Technology designed to provide a better view of metabolic health by combining glucose information with context around activities of daily living in one device.
- $58 million in funding led by Alpha Wave Ventures.
SAN DIEGO–(BUSINESS WIRE)–Biolinq Incorporated, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, today announced the completion of $58 million in financing led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical. J.P. Morgan served as placement agent to Biolinq in connection with the financing.
